Vir Biotechnology Stock News

The US Government to purchase from GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) an additional 600,000 doses of sotrovimab, an investigational monoclonal antibody for the

GlaxoSmithKline and Vir Biotechnology have brokered a deal with the U.S. government to provide an additional 600K doses of sotrovimab for early COVID-19.

GlaxoSmithKline GSK, -0.60% GSK, +0.83% and partner Vir Biotechnology VIR, +1.96% said Tuesday that the U.S. government will buy 600,000 doses of sotrovimab, an investigational monoclonal antibody for

These stocks are poised for a strong year.

These three COVID-19 stocks could rake in a tremendous amount of cash this year.

GlaxoSmithKline PLC GSK, -0.18% announced Thursday an agreement to supply the Government of Canada with 20,000 doses of Sotrovimab, the COVID-19 monoclonal antibody therapy the company developed with

SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will present at the 40th Annual J.P. Morgan

The stock price of Vir Biotechnology Inc (NASDAQ: VIR) increased by over 3% in the most recent trading session. This is why it happened.

Vir Biotechnology (NASDAQ:VIR) and CytRx (OTCMKTS:CYTR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability. Volatility & Risk Vir Biotechnology has a beta of -1.48, suggesting that its stock price is 248% []

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 400,022 shares of Vir Biotechnology stock in a transaction dated Monday, December 20th. The stock was sold at an average price of $52.73, for a total value of $21,093,160.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which […]

Vir Biotechnology (NASDAQ:VIR) had its price target hoisted by HC Wainwright from $200.00 to $300.00 in a research note released on Tuesday, Analyst Ratings Network reports. The brokerage currently has a buy rating on the stock. Other equities research analysts have also issued reports about the stock. JPMorgan Chase & Co. raised shares of Vir [] The post HC Wainwright Boosts Vir Biotechnology (NASDAQ:VIR) Price Target to $300.00 appeared first on ETF Daily News .

Vir Biotechnology (NASDAQ:VIR) had its price target increased by HC Wainwright from $200.00 to $300.00 in a report released on Tuesday, PriceTargets.com reports. The firm currently has a “buy” rating on the stock. Several other equities research analysts also recently weighed in on VIR. Robert W. Baird downgraded shares of Vir Biotechnology from a “neutral” […]

NEW YORK , Dec. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, KMX, NKE, PAYX, and CTXS. Full story available on Benzinga.com

Michael Yee, Managing Director at Jefferies, discusses Adagio and its treatment for COVID-19 as well as the outlook for Moderna in 2022 on Yahoo Finance Live.